Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

[Cytokeratin 18 as marker for non-invasive diagnosis and prognosis of acute and chronic liver diseases].

Canbay A, Feldstein A, Kronenberger B, Schulze-Osthoff K, Bantel H.

Z Gastroenterol. 2014 Mar;52(3):290-5. doi: 10.1055/s-0033-1356138. Epub 2014 Mar 12. German.

PMID:
24622872
[PubMed - in process]
2.

Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.

Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-Osthoff K, Bantel H.

Hepatology. 2012 Feb;55(2):455-64. doi: 10.1002/hep.24734. Epub 2011 Nov 29.

PMID:
21993925
[PubMed - indexed for MEDLINE]
3.

Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K.

J Viral Hepat. 2012 Apr;19(4):278-82. doi: 10.1111/j.1365-2893.2011.01546.x. Epub 2011 Nov 24.

PMID:
22404726
[PubMed - indexed for MEDLINE]
4.

Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease.

Yilmaz Y.

Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1103-9. doi: 10.1111/j.1365-2036.2009.04148.x. Epub 2009 Sep 21. Review.

PMID:
19769633
[PubMed - indexed for MEDLINE]
5.

Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis.

Chen J, Zhu Y, Zheng Q, Jiang J.

Hepatol Res. 2014 Aug;44(8):854-62. doi: 10.1111/hepr.12197. Epub 2013 Aug 15.

PMID:
23834322
[PubMed]
6.

Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ.

Gut. 2008 Apr;57(4):500-6. Epub 2007 Nov 19.

PMID:
18025069
[PubMed - indexed for MEDLINE]
7.

Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction.

Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U, Weigand MA.

Crit Care. 2009;13(3):R93. doi: 10.1186/cc7923. Epub 2009 Jun 18.

PMID:
19538738
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.

Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M.

Liver Int. 2012 Feb;32(2):279-86. doi: 10.1111/j.1478-3231.2011.02637.x. Epub 2011 Sep 9.

PMID:
22098614
[PubMed - indexed for MEDLINE]
9.

Evaluation of the diagnostic value of serum and tissue apoptotic cytokeratin-18 in patients with chronic hepatitis C.

Abdel Haleem H, Zayed N, Abdel Hafez H, Fouad A, Akl M, Hassan M, Hammam O, Morsy A, Saleh A, Seyam M, Zakaria Z, Zakaria S.

Arab J Gastroenterol. 2013 Jun;14(2):68-72. doi: 10.1016/j.ajg.2013.03.004. Epub 2013 Apr 28.

PMID:
23820504
[PubMed - indexed for MEDLINE]
10.

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.

Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW.

Aliment Pharmacol Ther. 2014 Feb;39(3):254-69. doi: 10.1111/apt.12569. Epub 2013 Dec 5.

PMID:
24308774
[PubMed - in process]
11.

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F.

J Hepatol. 2014 Jan;60(1):167-74. doi: 10.1016/j.jhep.2013.07.042. Epub 2013 Aug 20.

PMID:
23973932
[PubMed - in process]
12.

Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.

Valva P, De Matteo E, Galoppo M, Pedreira A, Giacove G, Lezama C, Marco I, Galoppo MC, Preciado MV.

Hum Pathol. 2008 Dec;39(12):1816-22. doi: 10.1016/j.humpath.2008.04.022. Epub 2008 Aug 20.

PMID:
18715620
[PubMed - indexed for MEDLINE]
13.

[Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].

Watanabe T, Takemura M, Saito K, Ito H, Hattori T, Sekine A, Yamada K, Kato T, Tomita E, Matsuoka T, Seishima M.

Rinsho Byori. 2013 Jan;61(1):19-24. Japanese.

PMID:
23672077
[PubMed - indexed for MEDLINE]
14.

Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A.

Aliment Pharmacol Ther. 2013 Feb;37(4):392-400. doi: 10.1111/apt.12186. Epub 2012 Dec 20. Review.

PMID:
23278163
[PubMed - indexed for MEDLINE]
15.

Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children.

Valva P, Casciato P, Lezama C, Galoppo M, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV.

PLoS One. 2013;8(1):e53519. doi: 10.1371/journal.pone.0053519. Epub 2013 Jan 11.

PMID:
23326448
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ.

Hepatology. 2009 Oct;50(4):1072-8. doi: 10.1002/hep.23050.

PMID:
19585618
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?

Castera L, Bedossa P.

Liver Int. 2011 Jan;31 Suppl 1:13-7. doi: 10.1111/j.1478-3231.2010.02380.x. Review.

PMID:
21205132
[PubMed - indexed for MEDLINE]
18.

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.

Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, Chim AM, Yeung DK, Yu J, Chu WC, Wong VW.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1057-66. doi: 10.1111/apt.12091. Epub 2012 Oct 16.

PMID:
23066946
[PubMed - indexed for MEDLINE]
19.

Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

Stevenson M, Lloyd-Jones M, Morgan MY, Wong R.

Health Technol Assess. 2012;16(4):1-174. doi: 10.3310/hta16040. Review.

PMID:
22333291
[PubMed - indexed for MEDLINE]
Free Article
20.

Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy?

Phillips MG, Preedy VR, Hughes RD.

Eur J Gastroenterol Hepatol. 2003 Sep;15(9):941-4. Review.

PMID:
12923364
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk